DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse" report to their offering.
Pain therapeutics market is forecast to grow from US$19.7 Billion in 2016 to US$28.8 Billion in 2023 at a compound annual growth rate (CAGR) of 5.5%
The US market alone is forecast to be worth US$13.5 Billion in 2023, accounting for 45.2% of the overall pain therapeutics market. Generic products are the main source of market revenue, accounting for over 50% of total market revenue in 2016. This is due mainly to the widespread usage (particularly in the US) of generic opioids, which are far more expensive than other generic analgesics.
There are 817 products in the pain therapeutics pipeline, including 75 for migraine, 118 for inflammatory pain and 255 for neuropathic pain. Some 63% of the pipeline is in the early drug development stages. The most promising drugs within the pipeline include those drugs belonging to the new class of migraine medication, the CGRPR antagonists that have been shown to be an effective preventative therapy for migraines. This class of drugs is forecast to generate an aggregate of US$5 Billion revenue by 2023.
A total of 363 licensing deals for pain therapeutics were completed between 2006 and April 2017, with an aggregate disclosed value of US$11.8 Billion. This highlights pharmaceutical company's interest in investment in analgesics. These deals varied considerably in terms of value, ranging from US$20,000 to US$1.5 Billion. Over 40 deals were valued at less than US$10m, while 19 were valued above US$200m.
Key Topics Covered:
2 Key Marketed Products
3 Pipeline Landscape Assessment
4 Multi-scenario Market Forecast to 2022
5 Company Analysis and Positioning
6 Strategic Consolidations
- Daiichi Sankyo
- Eli Lilly
For more information about this report visit https://www.researchandmarkets.com/research/fbx39g/global_pain